Thomas Dejoie

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 408 citations · Full text

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 273 citations · Full text

Active smoking compromises IVF outcome and affects ovarian reserve

Thomas Fréour, Damien Masson, S. Mirallié et al. · Reproductive BioMedicine Online · 2008 · 173 citations · Full text

Infertility, Hormonal Contraceptive, Fertility +8

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 167 citations · Full text

Hematological Malignancy, Medicine, Autologous Stem-cell Transplant +6